{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:12:27Z","timestamp":1790835147183,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Institut National de la Recherche et de la Sant\u00e9 (INSERM)"},{"DOI":"10.13039\/501100007822","name":"Bordeaux University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007822","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006751","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Salud Mental","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006751","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006751","name":"CIBERSAM","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006751","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MINECO-FEDER","award":["SAF2015-68346-P"],"award-info":[{"award-number":["SAF2015-68346-P"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.neuropharm.2017.04.001","type":"journal-article","created":{"date-parts":[[2017,4,5]],"date-time":"2017-04-05T06:31:34Z","timestamp":1491373894000},"page":"91-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Opposite control of mesocortical and mesoaccumbal dopamine pathways by serotonin2B receptor blockade: Involvement of medial prefrontal cortex serotonin1A receptors"],"prefix":"10.1016","volume":"119","author":[{"given":"C\u00e9line","family":"Devroye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser","family":"Haddjeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline","family":"Cathala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"Rovera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Drago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Vincenzo","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Artigas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Spampinato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2017.04.001_bib1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00213-009-1521-8","article-title":"Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in\u00a0vivo","volume":"205","author":"Abbas","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.04.001_bib2","first-page":"1","article-title":"Feedback regulation of central monoaminergic neurons: evidence from single cell recording studies","volume":"3","author":"Aghajanian","year":"1978","journal-title":"Essays Neurochem. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2017.04.001_bib3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1124\/jpet.105.087163","article-title":"Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain","volume":"315","author":"Assi\u00e9","year":"2005","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.04.001_bib4","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/j.1471-4159.2010.06848.x","article-title":"The central serotonin 2B receptor: a new pharmacological target to modulate the mesoaccumbens dopaminergic pathway activity","volume":"114","author":"Auclair","year":"2010","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2017.04.001_bib5","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/cne.901790311","article-title":"An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat","volume":"179","author":"Azmitia","year":"1978","journal-title":"J.\u00a0Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2017.04.001_bib6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0006-8993(02)02504-0","article-title":"Nuclei and subnuclei gene expression profiling in mammalian brain","volume":"943","author":"Bonaventure","year":"2002","journal-title":"Brain. Res."},{"key":"10.1016\/j.neuropharm.2017.04.001_bib7","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/sj.bjp.0702632","article-title":"RS-127445: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist","volume":"127","author":"Bonhaus","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.04.001_bib8","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1126\/science.3854","article-title":"Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs","volume":"192","author":"Creese","year":"1976","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2017.04.001_bib9","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.neuropharm.2015.06.012","article-title":"Central serotonin(2B) receptor blockade inhibits cocaine-induced hyperlocomotion independently of changes of subcortical dopamine outflow","volume":"97","author":"Devroye","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2017.04.001_bib10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.neuropharm.2016.05.024","article-title":"Differential control of dopamine ascending pathways by serotonin2B receptor antagonists: new opportunities for the treatment of schizophrenia","volume":"109","author":"Devroye","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2017.04.001_bib11","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/mp.2011.159","article-title":"5-HT(2B) receptors are required for serotonin-selective antidepressant actions","volume":"17","author":"Diaz","year":"2012","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.04.001_bib12","doi-asserted-by":"crossref","first-page":"10831","DOI":"10.1523\/JNEUROSCI.2999-05.2005","article-title":"Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action","volume":"25","author":"D\u00edaz-Mataix","year":"2005","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.04.001_bib13","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1523\/JNEUROSCI.5723-07.2008","article-title":"Serotonin 5-HT2B receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in\u00a0vivo and in\u00a0vitro","volume":"28","author":"Doly","year":"2008","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.04.001_bib14","doi-asserted-by":"crossref","first-page":"e7952","DOI":"10.1371\/journal.pone.0007952","article-title":"Role of serotonin via 5-HT2B receptors in the reinforcing effects of MDMA in mice","volume":"4","author":"Doly","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.neuropharm.2017.04.001_bib15","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.ebiom.2015.06.023","article-title":"Astroglial control of the antidepressant-like effects of prefrontal cortex deep brain stimulation","volume":"2","author":"Eti\u00e9vant","year":"2015","journal-title":"EbioMedicine"},{"key":"10.1016\/j.neuropharm.2017.04.001_bib16","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0166-4328(96)00118-0","article-title":"Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist","volume":"73","author":"Fletcher","year":"1996","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2017.04.001_bib17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/cne.20738","article-title":"Prefrontal cortex in the rat: projections to subcortical autonomic, motor, and limbic centers","volume":"492","author":"Gabbott","year":"2005","journal-title":"J.\u00a0Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2017.04.001_bib18","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0006-8993(99)02346-X","article-title":"The effect of serotonin1A receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens","volume":"858","author":"Ichikawa","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2017.04.001_bib19","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1046\/j.1471-4159.2001.00154.x","article-title":"5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release","volume":"76","author":"Ichikawa","year":"2001","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2017.04.001_bib20","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1124\/jpet.109.160432","article-title":"Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)\/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in\u00a0vitro and neurochemical profile","volume":"333","author":"Kiss","year":"2010","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.04.001_bib21","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/0014-2999(94)90812-5","article-title":"Selective in\u00a0vivo labelling of brain 5-HT1A receptors by [3H]WAY 100635 in the mouse","volume":"271","author":"Laporte","year":"1994","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.04.001_bib22","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1096\/fj.06-5724com","article-title":"Serotonin transport and serotonin transporter-mediated antidepressant recognition are controlled by 5-HT2B receptor signaling in serotonergic neuronal cells","volume":"20","author":"Launay","year":"2006","journal-title":"FASEB J."},{"key":"10.1016\/j.neuropharm.2017.04.001_bib23","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1471-4159.2009.06356.x","article-title":"In\u00a0vivo evidence that constitutive activity of serotonin2C receptors in the medial prefrontal cortex participates in the control of dopamine release in the rat nucleus accumbens: differential effects of inverse agonist versus antagonist","volume":"111","author":"Leggio","year":"2009","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2017.04.001_bib24","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1093\/cercor\/bhr220","article-title":"5-HT1A receptor agonists enhance pyramidal cell firing in prefrontal cortex through a preferential action on GABA interneurons","volume":"22","author":"Llad\u00f3-Pelfort","year":"2012","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.neuropharm.2017.04.001_bib25","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.coph.2011.02.007","article-title":"The role of serotonin receptors in the action of atypical antipsychotic drugs","volume":"11","author":"Meltzer","year":"2011","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.04.001_bib26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.neulet.2005.10.044","article-title":"Allosteric modulation of the effects of the 5-HT reuptake inhibitor escitalopram on the rat hippocampal synaptic plasticity","volume":"395","author":"Mnie-Filali","year":"2006","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2017.04.001_bib27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.pneurobio.2007.01.001","article-title":"Serotonin and psychostimulant addiction: focus on 5-HT1A-receptors","volume":"81","author":"M\u00fcller","year":"2007","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2017.04.001_bib28","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/sj.npp.1301414","article-title":"Differential regulation of the mesoaccumbens dopamine circuit by serotonin2C receptors in the ventral tegmental area and the nucleus accumbens: an in\u00a0vivo microdialysis study with cocaine","volume":"33","author":"Navailles","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.04.001_bib29","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00213-011-2247-y","article-title":"Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties","volume":"216","author":"Newman-Tancredi","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.04.001_bib30","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2005"},{"key":"10.1016\/j.neuropharm.2017.04.001_bib31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0006-8993(85)90856-X","article-title":"Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. serotonin-1 receptors","volume":"346","author":"Pazos","year":"1985","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2017.04.001_bib32","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1126\/science.1144640","article-title":"Astrocytes potentiate transmitter release at single hippocampal synapses","volume":"317","author":"Perea","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2017.04.001_bib33","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.tins.2009.05.001","article-title":"Tripartite synapses: astrocytes process and control synaptic information","volume":"32","author":"Perea","year":"2009","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2017.04.001_bib34","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1038\/npp.2015.126","article-title":"Mice lacking the serotonin Htr2B receptor gene present an antipsychotic-sensitive schizophrenic-like phenotype","volume":"40","author":"Pitychoutis","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.04.001_bib35","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1523\/JNEUROSCI.12-02-00440.1992","article-title":"Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding","volume":"12","author":"Pompeiano","year":"1992","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.04.001_bib36","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1124\/jpet.110.166710","article-title":"Behavioral indices in antipsychotic drug discovery","volume":"333","author":"Porsolt","year":"2010","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.04.001_bib37","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0197-0186(99)00134-5","article-title":"5-Hydroxytryptamine2B receptors stimulate Ca2+ increases in cultured astrocytes from three different brain regions","volume":"36","author":"Sand\u00e9n","year":"2000","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2017.04.001_bib38","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/cercor\/bhh070","article-title":"Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex","volume":"14","author":"Santana","year":"2004","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.neuropharm.2017.04.001_bib39","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1196\/annals.1300.066","article-title":"Anatomical substrates for glutamate-dopamine interactions: evidence for specificity of connections and extrasynaptic actions","volume":"1003","author":"Sesack","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2017.04.001_bib40","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/0269881107082944","article-title":"Asenapine: a novel psychopharmacologic agent with a unique human receptor signature","volume":"23","author":"Shahid","year":"2009","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.04.001_bib41","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.04.001_bib42","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0165-0173(99)00048-X","article-title":"Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs","volume":"31","author":"Svensson","year":"2000","journal-title":"Brain Res. Brain Res. Rev."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817301314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817301314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T12:16:35Z","timestamp":1719144995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390817301314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":42,"alternative-id":["S0028390817301314"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.04.001","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opposite control of mesocortical and mesoaccumbal dopamine pathways by serotonin2B receptor blockade: Involvement of medial prefrontal cortex serotonin1A receptors","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}